Relapsed/refractory primary central nervous system lymphoma (PCNSL) and secondary
central nervous system lymphoma (SCNSL) are associated with short survival and represent …

Chimeric antigen receptor (CAR) T-cell systemic immunotherapy has revolutionized how
clinicians treat several refractory and relapsed hematologic malignancies. Due to its peculiar …

Chimeric antigen receptor T-cell therapy (CAR-T) has been successful in treating
relapsed/refractory B-cell lymphomas. However, its role in the treatment of diseases …

Immune thrombotic thrombocytopenic purpura (iTTP) is a rare, life-threatening autoimmune
disorder caused by a disintegrin and metalloproteinase with thrombospondin type 1 motif …

Background Chimeric antigen receptor (CAR) T-cells targeting CD19 have been established
as a leading engineered T-cell therapy for B-cell lymphomas; however, data for patients with …

Chimeric antigen receptor (CAR) T-cell therapy (CART) for central nervous system
lymphoma (CNSL) is a promising strategy, yet responses are frequently not durable …

Data on outcome of CD19-directed chimeric antigen receptor T-cell (CAR-T) therapy for
patients with large B-cell lymphoma (LBCL) with secondary central nervous system (CNS) …

The therapeutic success and widespread approval of genetically engineered T cells for a
variety of hematologic malignancies spurred the development of synthetic cell-based …

Secondary central nervous system (CNS) lymphoma (SCNSL) is a rare but clinically
challenging scenario with historically disappointing outcomes. SCNSL refers to lymphoma …

Lymphoma occurring in the central nervous system is considered primary central nervous
system lymphoma (PCNSL), usually without systematic lesions. Over the last few decades, a …